| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
63,980,000 |
| Market
Cap: |
607.17(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.22 - $11.59 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 18.6 |
| Insider 6 Months : 18.6 |
| Insider 3/6 Months : 37.7 |
|
| Guru Rank Number : 245 |
| Guru Rank Value : 4.8 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Theravance Biopharma is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicine medicines. Co.'s program include: YUPELRI™ (revefenacin) inhalation solution, nebulized long-acting muscarinic antagonist for the maintenance treatment of chronic obstructive pulmonary disease; and Lung-selective, Nebulized Pan-Janus Kinase (JAK) Inhibitor (Nezulcitinib), a lung-selective, nebulized JAK inhibitor, in clinical development for the potential treatment of hospitalized patients with acute lung injury caused by Coronavirus Disease 2019.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,499,124 |
1,499,124 |
1,499,124 |
1,499,124 |
| Total Buy Value |
$13,117,335 |
$13,117,335 |
$13,117,335 |
$13,117,335 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
1,254 |
5,114 |
22,963 |
172,089 |
| Total Sell Value |
$10,922 |
$50,468 |
$231,475 |
$1,835,193 |
| Total People Sold |
1 |
2 |
2 |
4 |
| Total Sell Transactions |
1 |
3 |
11 |
21 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-08-20 |
4 |
D |
$26.95 |
$188,785 |
D/D |
(7,005) |
91,119 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-08-15 |
4 |
S |
$26.71 |
$1,110,655 |
D/D |
(41,539) |
171,049 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-08-14 |
4 |
S |
$27.74 |
$61,136 |
D/D |
(2,204) |
212,588 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-08-08 |
4 |
S |
$27.85 |
$706,182 |
D/D |
(25,355) |
98,124 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-08-07 |
4 |
S |
$28.03 |
$168,393 |
D/D |
(5,945) |
123,479 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-06-08 |
4 |
S |
$23.66 |
$92,260 |
D/D |
(3,900) |
129,424 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-06-06 |
4 |
S |
$24.09 |
$244,268 |
D/D |
(10,140) |
133,324 |
|
- |
|
| Malkiel Burton G |
Director |
– • – |
2018-05-21 |
4 |
B |
$22.54 |
$22,540 |
D/D |
1,000 |
56,757 |
2.39 |
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$447,887 |
D/D |
(18,424) |
227,810 |
|
- |
|
| Hegde Sharathchandra S |
SVP, Research |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$464,394 |
D/D |
(19,103) |
174,258 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$530,250 |
D/D |
(21,812) |
143,464 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$474,628 |
D/D |
(19,524) |
178,654 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2018-05-20 |
4 |
D |
$24.31 |
$1,643,769 |
D/D |
(67,617) |
919,620 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$516,101 |
D/D |
(21,230) |
214,792 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$456,517 |
D/D |
(18,779) |
167,025 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2018-05-20 |
4 |
D |
$24.31 |
$656,151 |
D/D |
(26,991) |
148,962 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-05-18 |
4 |
S |
$24.29 |
$242,877 |
D/D |
(10,000) |
236,022 |
|
- |
|
| Hegde Sharathchandra S |
SVP, Research |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
193,361 |
|
- |
|
| Pasqualone Frank |
SVP, Chief Comm Ops Officer |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
246,234 |
|
- |
|
| Haumann Brett K |
SVP Clin Dev & Chief Med Ofc |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
175,953 |
|
- |
|
| Worboys Philip D |
SVP, Translational Science |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
198,178 |
|
- |
|
| Shafer Bradford J |
EVP, Gen. Counsel, Secretary |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
165,276 |
|
- |
|
| Winningham Rick E |
Chief Executive Officer |
• • – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
105,000 |
987,237 |
|
- |
|
| Gala Renee D |
SVP, Chief Financial Officer |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
246,022 |
|
- |
|
| Pitzer Kenneth R |
SVP, Prod Strat & Comm Plng |
• – – |
2018-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
33,750 |
185,804 |
|
- |
|
530 Records found
|
|
Page 13 of 22 |
|
|
0.05 (0.52%) 
